These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 27608846)

  • 41. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
    Kurmasheva RT; Reynolds CP; Kang MH; Allievi C; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 May; 61(5):922-4. PubMed ID: 24166988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Hoch U; Staschen CM; Johnson RK; Eldon MA
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
    BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
    Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
    Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
    Keil A; Frese-Schaper M; Steiner SK; Körner M; Schmid RA; Frese S
    Arthritis Rheumatol; 2015 Jul; 67(7):1858-67. PubMed ID: 25779651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MGI 114: augmentation of antitumor activity when combined with topotecan.
    Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
    J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
    Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
    Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
    Nekkanti V; Venkateswarlu V; Ansari KA; Pillai R
    Curr Drug Deliv; 2011 Nov; 8(6):661-6. PubMed ID: 22313161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance.
    Alferiev IS; Guerrero DT; Guan P; Nguyen F; Kolla V; Soberman D; Pressly BB; Fishbein I; Brodeur GM; Chorny M
    FASEB J; 2022 Mar; 36(3):e22213. PubMed ID: 35192728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
    Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
    Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
    Lian C; Cao S; Zeng W; Li Y; Su J; Li J; Zhao S; Wu L; Tao J; Zhou J; Chen X; Peng C
    Biochem Pharmacol; 2020 Jan; 171():113716. PubMed ID: 31751535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
    Yano H; Kayukawa S; Iida S; Nakagawa C; Oguri T; Sanda T; Ding J; Mori F; Ito A; Ri M; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Inagaki H; Suzuki A; Ueda R
    Cancer Sci; 2008 Nov; 99(11):2309-14. PubMed ID: 18771527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
    Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
    Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
    PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
    Amzerin M; Mokrim M; Errihani H; Piccart MJ
    J Med Case Rep; 2015 Feb; 9():5. PubMed ID: 25971303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
    Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
    Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
    Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
    Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
    Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Yu PY; Gardner HL; Roberts R; Cam H; Hariharan S; Ren L; LeBlanc AK; Xiao H; Lin J; Guttridge DC; Mo X; Bennett CE; Coss CC; Ling Y; Phelps MA; Houghton P; London CA
    PLoS One; 2017; 12(7):e0181885. PubMed ID: 28750090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.